Leukogene Therapeutics Inc Profile last edited on: 3/6/2023
CAGE: 6T1N7
UEI: DDD1BU62TM94
Business Identifier: Novel drug discovery and development in hematologic malignancies 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
25 Hunters Hill Drive
Morgantown, PA 19543
Morgantown, PA 19543
| (215) 272-5203 |
| N/A |
| N/A |
Location: Single
Congr. District: 06
County: Berks
Congr. District: 06
County: Berks
Public Profile
Leukogene Therapeutics, Inc. operates as an oncology drug discovery and development company focused on developing treatments for patients with incurable blood cancers like Multiple Myeloma.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 2 | NIH | $2,197,324 | |
| Project Title: AGR2-Superantigen Vaccine Conjugate for the Treatment of Pancreaticductal Adenocarcinoma | ||||
| 2021 | 1 | NIH | $362,118 | |
| Project Title: Bispecific T cell engagers for the treatment of pancreatic ductal adenocarcinoma | ||||
| 2019 | 2 | NIH | $2,222,958 | |
| Project Title: Proteasome Inhibitor Re-Sensitizing Molecules for Treatment of Refractory Multiple Myeloma | ||||
| 2013 | 1 | NIH | $224,701 | |
| Project Title: Inhibitors of Igh Gene Enhancers for the Treatment of Multiple Myeloma | ||||
Key People / Management
Frank W Marcoux
Nathan G Dolloff -- Principal
Reeder Robinson
Nathan G Dolloff -- Principal
Reeder Robinson
Company News
There are no news available.
